FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF
申请人:Sarepta Therapeutics, Inc.
公开号:US20140330006A1
公开(公告)日:2014-11-06
Functionally-modified oligonucleotide analogues comprising modified intersubunit linkages and/or modified 3′ and/or 5′-end groups are provided. The disclosed compounds are useful for the treatment of diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.
A Lewis Base Catalysis Approach for the Photoredox Activation of Boronic Acids and Esters
作者:Fabio Lima、Upendra K. Sharma、Lars Grunenberg、Debasmita Saha、Sandra Johannsen、Joerg Sedelmeier、Erik V. Van der Eycken、Steven V. Ley
DOI:10.1002/anie.201709690
日期:2017.11.20
either boronic acids or esters. This system enabled a wide range of alkyl boronic esters and aryl or alkyl boronic acids to react with electron-deficient olefins via radical addition to efficiently form C-C coupled products in a redox-neutral fashion. The Lewis base catalyst was shown to form a redox-active complex with either the boronic esters or the trimeric form of the boronic acids (boroxines) in
Photochemical addition of tertiary amines to electrophilic cyclopropanes via single electron transfer
作者:Hideo Tomioka、Hiroshi Miyagawa
DOI:10.1039/c39880001183
日期:——
Irradiation of arylcyclopropanes bearing at least one electron-withdrawing group with a tertiaryamine in acetonitrile resulted in the formation of the regioselective addition product of the amine along with the reduction product.
OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS
申请人:Sarepta Therapeutics, Inc.
公开号:US20150073140A1
公开(公告)日:2015-03-12
Oligonucleotide analogues comprising modified intersubunit linkages and/or modified 3′ and/or 5′-end groups are provided. The disclosed compounds are useful for the treatment of diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.
Oligonucleotide analogues conjugated to carrier peptides are provided. The disclosed compounds are useful for the treatment of various diseases, for example diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.